( ) was the subject of a significant rise in short interest during March. On March 31, there were 7,500 shorted shares. This is a 368.8% increase from the total of 1,600 on March 15. The short-interest rate is currently 0.1 day based on an average daily share volume of 63 200 shares.
Hedge Funds weigh in on PURE Bioscience
Recently, a hedge fund bought a new stake of PURE Bioscience. The latest Form 13F filed with the Securities and Exchange Commission shows that the firm acquired 809,809 shares of the company's stock valued at approximately $162,000 during the third quarter. The firm purchased 809,809 of the company's shares, worth approximately $162,000, from the Securities and Exchange Commission. IFG Advisory LLC held approximately 0.92% PURE Bioscience stock at the end the most recent quarterly. During Friday's midday trading, a share of 888 gained $0.02 to reach $0.10. Trading volume was 120,200 shares versus its average of 34,946. The 50-day simple moving is $0.14, and the 200-day simple moving is also $0.14. The company's market capitalization is $11.14million, with a P/E ratio of -2.50. Its beta value is 0.21. PURE Bioscience's 1-year low is $0.07, and its 1-year high is $0.24.
PURE Bioscience Company profile
PURE Bioscience, Inc is engaged in the discovery, creation, and commercialization antimicrobial products that are proprietary for hygienic and pathogen control. It provides silver dihydrogen citrate based disinfecting and cleaning products. Michael L. Krall founded the company on August 24, 1992. Its headquarters are in Rancho Cucamonga.
MarketBeat.com offers a FREE daily email newsletter